** Cancer drug developer Aura Biosciences' AURA.O shares rise as much as 9.8%; last up 7.3% at $5.26
** AURA announces pricing of public offering of common stock and warrants at $4.90 apiece for gross proceeds of $75 million
** Offering priced at stock's last close of $4.90
** Insiders had indicated on buying up to $350,000 in shares in offering, according to SEC filing
** Leerink Partners and Evercore ISI were joint book-running managers for offering
** Boston, Massachusetts-based AURA plans to use proceeds to advance its clinical programs and other purposes
** Separately, AURA posts Q1 loss of $27.5 million, up from $19.7 million loss a year ago
** AURA had cash and cash equivalents and marketable securities totaling $128 million, as of March 31
** All seven brokerages covering stock rate "buy" or higher; median PT $22.50 - data compiled by LSEG
** As of last close, stock down 40.4% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.